These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 23558526)

  • 1. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
    Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I
    Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.
    Li J; Spensberger D; Ahn JS; Anand S; Beer PA; Ghevaert C; Chen E; Forrai A; Scott LM; Ferreira R; Campbell PJ; Watson SP; Liu P; Erber WN; Huntly BJ; Ottersbach K; Green AR
    Blood; 2010 Sep; 116(9):1528-38. PubMed ID: 20489053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
    Usart M; Stetka J; Luque Paz D; Hansen N; Kimmerlin Q; Almeida Fonseca T; Lock M; Kubovcakova L; Karjalainen R; Hao-Shen H; Börsch A; El Taher A; Schulz J; Leroux JC; Dirnhofer S; Skoda RC
    Blood; 2024 Jun; 143(24):2490-2503. PubMed ID: 38493481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
    Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
    Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
    Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
    Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.
    Lundberg P; Takizawa H; Kubovcakova L; Guo G; Hao-Shen H; Dirnhofer S; Orkin SH; Manz MG; Skoda RC
    J Exp Med; 2014 Oct; 211(11):2213-30. PubMed ID: 25288396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.
    Grisouard J; Shimizu T; Duek A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
    Blood; 2015 Mar; 125(13):2131-40. PubMed ID: 25595737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN).
    Glück M; Dally L; Jücker M; Ehm P
    Int J Biochem Cell Biol; 2022 Aug; 149():106229. PubMed ID: 35609769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.
    Yan D; Jobe F; Hutchison RE; Mohi G
    Leukemia; 2015 Oct; 29(10):2050-61. PubMed ID: 26044284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.
    Duek A; Lundberg P; Shimizu T; Grisouard J; Karow A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
    Blood; 2014 Jun; 123(25):3943-50. PubMed ID: 24820309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
    Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
    Baran-Marszak F; Magdoud H; Desterke C; Alvarado A; Roger C; Harel S; Mazoyer E; Cassinat B; Chevret S; Tonetti C; Giraudier S; Fenaux P; Cymbalista F; Varin-Blank N; Le Bousse-Kerdilès MC; Kiladjian JJ; Velazquez L
    Blood; 2010 Dec; 116(26):5961-71. PubMed ID: 20870899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
    Pomicter AD; Eiring AM; Senina AV; Zabriskie MS; Marvin JE; Prchal JT; O'Hare T; Deininger MW
    Exp Hematol; 2015 Jul; 43(7):537-45.e1-11. PubMed ID: 25912019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
    Grimwade LF; Happerfield L; Tristram C; McIntosh G; Rees M; Bench AJ; Boyd EM; Hall M; Quinn A; Piggott N; Scorer P; Scott MA; Erber WN
    Br J Haematol; 2009 Nov; 147(4):495-506. PubMed ID: 19747364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.